Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. By Rebecca Robbins and Dani Blum from NYT (New York Times) Health
Read more.